{"entity":{"id":"nct05024097","kind":"trial","name":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for","aka":["PANTHER"],"tldr":"A phase 2 trial of zimberelimab in colorectal cancer, run by Weill Medical College of Cornell University, now recruiting.","summary":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. is a phase 2, interventional study registered as NCT05024097 by Weill Medical College of Cornell University, with a registry enrolment figure of 43 participants, started 2022-03-31 and due to reach its primary completion in 2026-12. Interventions recorded: Etrumadenant (AB928); Radiation therapy; FOLFOX regimen; Zimberelimab (AB122). Conditions listed: Rectal Cancer. Primary outcome: Number of treated patients who achieve complete pathologic response. Colorectal eligibility wording from the registry: \"* Histologically confirmed diagnosis of adenocarcinoma of the rectum\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05024097","url":"https://clinicaltrials.gov/study/NCT05024097"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["zimberelimab"],"companies":["arcus-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05024097","phase":"2","setting":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.","sponsor":"Weill Medical College of Cornell University","participation":[{"nct":"NCT05024097","source":"https://clinicaltrials.gov/study/NCT05024097","fetchedAt":"2026-10-07T16:53:32.717Z","studySha256":"457be2966e2a47b29534a10952e05e5103e035b5b3b487f4c633b62e65f7b05f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-29","leadSponsor":"Weill Medical College of Cornell University","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"90 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":43,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["United States"]}],"started":"2022-03-31","startedType":"actual","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05024097/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"company":[{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}